X4 Pharmaceuticals, Inc. - Common Stock (XFOR)

BOSTON, Oct. 23, 2025 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR) (“X4” or the “Company”), a company driven to improve the lives of people with rare hematology diseases, today announced that it has commenced an underwritten public offering of shares of its common stock or, in lieu of common stock to certain investors that so choose, pre-funded warrants to purchase shares of its common stock. In addition, X4 expects to grant the underwriters an option for a period of 30 days to purchase up to a number of additional shares of common stock equal to 15% of the shares of common stock and pre-funded warrants initially offered at the public offering price, less underwriting discounts and commissions. The proposed public offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed or as to the actual size or terms of the offering. All of the securities are being offered by X4.

Organizational restructuring including a 50% reduction in workforce that is anticipated to result in annualized cost savings of approximately $13M

Low-priced momentum plays are heating up the tape as earnings beats, insider buys, and strategic deals fuel speculation ahead of key catalysts. From crypto-backed balance sheets to mass retail expansion and sustainable technology breakthroughs, these sub-$5 companies are lining up for potential breakout runs. Traders scanning for under-the-radar opportunities may find this week’s lineup too hot to ignore.

This article provides a quick look into four (4) additional undervalued/undiscovered stocks, take a look now.